Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-09Clinical Trial Update: A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD [Phase 4]
Phase 4 trial update reporting efficacy and safety of NVA237 in moderate to severe COPD, completed with posted results.
-
CLINICAL_TRIALS withdrawal · 2019-08-07Clinical Trial Update: Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD [Phase 4]
A Phase 4 clinical trial investigating the effect of Symbicort on histone acetyltransferase and HDAC activity in sputum macrophages for COPD…
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]
Phase 3 trial update evaluating the relationship between albuterol multidose dry powder inhaler use with an eModule (eMDPI) and exacerbation…
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD [Phase 1]
Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and impact on inflammation of oral BI 1026706 in patients with chronic obst…
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]
A Phase 2 pharmacodynamic and pharmacokinetic dose-ranging study evaluated inhaled tiotropium bromide solution in patients with mild to mode…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis [Phase 4]
Phase 4 trial update comparing inhaled LAMA, LAMA+LABA, and ICS+LABA in patients with COPD and bronchiectasis.
-
CLINICAL_TRIALS trial_result · 2019-07-24Clinical Trial Update: A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD [Phase 3]
A Phase 3 trial evaluating the effects of PT001 and PT005 MDI on image-based parameters in subjects with moderate to severe COPD has complet…
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD [Phase 4]
Phase 4 clinical trial update evaluating whether an inhaled corticosteroid provides additional benefit when used with tiotropium in COPD pat…
-
FDA approval · 2019-07-22FDA Approved: SEREVENT DISKUS — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for SEREVENT DISKUS (salmeterol xinafoate) submitted by GlaxoSmithKline LLC.
-
CLINICAL_TRIALS trial_result · 2019-07-22Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]
Phase 2 clinical trial evaluating the pharmacokinetics, safety, and tolerability of a twice-daily fixed-dose combination of aclidinium bromi…
-
CLINICAL_TRIALS trial_result · 2019-07-22Clinical Trial Update: Alpha-1 Carrier Genomics Study
A completed clinical trial study on Alpha-1 Antitrypsin Deficiency and Emphysema with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-07-18Clinical Trial Update: Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD [Phase 4]
Phase 4 trial update evaluating sedation and physiological effects of intranasal dexmedetomidine in patients with severe COPD.
-
CLINICAL_TRIALS research · 2019-07-15Clinical Trial Update: Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]
Phase 3 trial comparing closed therapy of FF/UMEC/VI versus open therapy FF/VI with UMEC in COPD; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-07-15Clinical Trial Update: A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
A 24-week Phase 4 trial comparing umeclidinium/vilanterol (UMEC/VI), umeclidinium (UMEC) alone, and salmeterol in COPD patients has complete…
-
CLINICAL_TRIALS trial_result · 2019-07-12Clinical Trial Update: Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease [Phase 4]
Phase 4 clinical trial update evaluating aclidinium/formoterol on nighttime lung function and morning symptoms in COPD.
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD [Phase 3]
A Phase 3 clinical trial evaluating symptom-driven maintenance and reliever treatment to prevent exacerbations in COPD is ongoing or pending…
-
CLINICAL_TRIALS trial_result · 2019-07-10Clinical Trial Update: A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD [NA]
Pilot study evaluating AVAPS-AE therapy for sleep-disordered breathing with comorbid COPD; the trial is terminated with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: This Study Include Chronic Obstructive Pulmonary Disease(COPD) Patients . Patients Were Vitamin D Deficient Age Range 40 to 80 Years, Smokers Patients Were Advised to Take Either Placebo or Vitamin D3 . Antioxidant Enzymes Were Assessed at Baseline and at 26th Weeks. [Phase 2]
Phase 2 clinical trial assessing vitamin D3 versus placebo in vitamin D deficient COPD patients, with antioxidant enzymes measured over 26 w…
-
CLINICAL_TRIALS trial_result · 2019-07-08Clinical Trial Update: Comparative Effectiveness of COPD Treatments
A completed clinical trial evaluating comparative effectiveness of COPD treatments; results posted in 2019.
-
CLINICAL_TRIALS research · 2019-07-08Clinical Trial Update: The Trajectory of Physical Activity Following Pulmonary Rehabilitation
Clinical trial update on how physical activity changes over time after a pulmonary rehabilitation program.
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers [Phase 1]
Phase 1 trial evaluating pharmacokinetic comparability of benralizumab delivered via accessorized pre-filled syringe versus autoinjector in …
-
EMA withdrawal · 2019-07-02EMA Withdrawn: Airexar Spiromax (salmeterol;fluticasone propionate) — Teva B.V.
EMA has withdrawn Airexar Spiromax (salmeterol; fluticasone propionate) from the market.
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI) [Phase 3]
Phase 3 trial evaluating inhaled umeclidinium (UMEC) in COPD patients using a novel dry powder inhaler; study completed with posted results …
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: Drug Utilization Study for Olodaterol
A completed clinical trial studying drug utilization of olodaterol in chronic obstructive pulmonary disease with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History [Phase 3]
Phase 3 trial update on benralizumab for moderate to very severe COPD with a history of exacerbations; results completed and posted in 2019.